
COVID-Flu Combination Vaccine Performs Well in Clinical Trial, Moderna Says
Published on June 10, 2024
A combination vaccine that targets both COVID-19 and influenza did well in a phase 3 clinical trial, Moderna said on June 10. Participants who received the combination shot had at least the same level of immune response as comparison cohorts, according to the Massachusetts-based pharmaceutical company, which produced one of the most widely used COVID-19 vaccines in the world. The trial compared the immune responses in adults aged 50 and older who received the combination vaccine with the responses in adults in the same age range who received an influenza vaccine and Moderna’s COVID-19 shot. Adults aged 65 and older in the comparison group received an enhanced flu vaccine....
